PE20090493A1 - DERIVADOS DE LA 6-CICLOAMINO-3-(PIRIDAZIN-4-IL)IMIDAZO[1,2-b]-PIRIDAZINA, SU PREPARACION Y SU APLICACION EN TERAPEUTICA - Google Patents
DERIVADOS DE LA 6-CICLOAMINO-3-(PIRIDAZIN-4-IL)IMIDAZO[1,2-b]-PIRIDAZINA, SU PREPARACION Y SU APLICACION EN TERAPEUTICAInfo
- Publication number
- PE20090493A1 PE20090493A1 PE2008001220A PE2008001220A PE20090493A1 PE 20090493 A1 PE20090493 A1 PE 20090493A1 PE 2008001220 A PE2008001220 A PE 2008001220A PE 2008001220 A PE2008001220 A PE 2008001220A PE 20090493 A1 PE20090493 A1 PE 20090493A1
- Authority
- PE
- Peru
- Prior art keywords
- pyridazin
- pyridazine
- alkylene
- alkyl
- imidazo
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Abstract
REFERIDA A COMPUESTOS DERIVADOS DE 6-CICLOAMINO-3-(PIRIDAZIN-4-IL)IMIDAZO[1,2-b]-PIRIDAZINA DE FORMULA (I) DONDE R2 ES ARILO OPCIONALMENTE SUSTITUIDO CON HALOGENO, ALQUILO(C1-C6), ALQUIL(C1-C6)-TIO, -CN, ENTRE OTROS; A ES ALQUILENO(C1-C7) OPCIONALMENTE SUSTITUIDO CON Ra; B ES ALQUILENO(C1-C7) OPCIONALMENTE SUSTITUIDO CON Rb; L ES N OPCIONALMENTE SUSTITUIDO CON UN Rc O Rd, O ES C SUSTITUIDO CON UN Re1 Y UN Rd, ENTRE OTROS, DONDE DOS GRUPOS Ra PUEDEN FORMAR UN ALQUILENO(C1-C6), Ra Y Rb PUEDEN FORMAR UN ENLACE O UN ALQUILENO(C1-C6), Ra Y Rc PUEDEN FORMAR UN ENLACE O UN ALQUILENO(C1-C6), Rb Y Rc PUEDEN FORMAR UN ENLACE O UN ALQUILENO(C1-C6); Rd ES H, ALQUILO(C1-C6), HIDROXI-ALQUILO(C1-C6), FLUOROALQUILO(C1-C6), ENTRE OTROS, Re1 ES -NR4R5, ENTRE OTROS, EN DONDE R4 Y R5 SON CADA UNO H, ALQUILO(C1-C6), CICLOALQUILO(C3-C7), ENTRE OTROS; R7 Y R8 SON CADA UNO H O ALQUILO(C1-C6). SON COMPUESTOS PREFERIDOS: 2-(4-FLUORO-FENIL)-6-PIPERAZIN-1-IL-3-PIRIDAZIN-4-IL-IMIDAZO[1,2-b]PIRIDAZINA, 2-(4-FLUORO-FENIL)-6-((R)-3-METIL-PIPERAZIN-1-IL)-3-PIRIDAZIN-4-IL-IMIDAZO[1,2-b]PIRIDAZINA, 6-(3,3-DIMETIL-PIPERAZIN-1-IL)-2-(4-FLUORO-FENIL)-3-PIRIDAZIN-4-IL-IMIDAZO[1,2-b]PIRIDAZINA, ENTRE OTROS. SE REFIERE TAMBIEN UN PROCEDIMIENTO DE PREPARACION Y A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON INHIBIDORES DE LA FOSFORILACION DE LA CASEINA POR LAS CASEINA CINASAS 1 EPSILON Y DELTA SIENDO UTILES EN EL TRATAMIENTO DEL INSOMNIO PRIMARIO, SOMNOLENCIA EXCESIVA, TRASTORNOS DE ANSIEDAD
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US95071107P | 2007-07-19 | 2007-07-19 | |
FR0705224A FR2918986B1 (fr) | 2007-07-19 | 2007-07-19 | Derives de 6-cycloamino-3-(pyridazin-4-yl)imidazo[1,2-b]- pyridazine, leur preparation et leur application en therapeutique |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20090493A1 true PE20090493A1 (es) | 2009-05-27 |
Family
ID=39183122
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2008001220A PE20090493A1 (es) | 2007-07-19 | 2008-07-17 | DERIVADOS DE LA 6-CICLOAMINO-3-(PIRIDAZIN-4-IL)IMIDAZO[1,2-b]-PIRIDAZINA, SU PREPARACION Y SU APLICACION EN TERAPEUTICA |
Country Status (22)
Country | Link |
---|---|
US (2) | US8455491B2 (es) |
EP (1) | EP2178879B1 (es) |
JP (1) | JP5431319B2 (es) |
KR (1) | KR20100041771A (es) |
CN (1) | CN101784552A (es) |
AR (1) | AR069272A1 (es) |
AU (1) | AU2008300449A1 (es) |
BR (1) | BRPI0814510A2 (es) |
CA (1) | CA2693116A1 (es) |
CL (1) | CL2008002138A1 (es) |
CO (1) | CO6290690A2 (es) |
EA (1) | EA016376B1 (es) |
ES (1) | ES2429765T3 (es) |
FR (1) | FR2918986B1 (es) |
MA (1) | MA31616B1 (es) |
NZ (1) | NZ582683A (es) |
PA (1) | PA8789901A1 (es) |
PE (1) | PE20090493A1 (es) |
TW (1) | TW200914456A (es) |
UY (1) | UY31236A1 (es) |
WO (1) | WO2009037394A2 (es) |
ZA (1) | ZA201001214B (es) |
Families Citing this family (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7638541B2 (en) | 2006-12-28 | 2009-12-29 | Metabolex Inc. | 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine |
BRPI0814294A2 (pt) | 2007-07-19 | 2015-02-03 | Metabolex Inc | Agonistas de receptor heterocíclico ligado a n para o tratamento do diabetes e de desordens metabólicas. |
US7868001B2 (en) * | 2007-11-02 | 2011-01-11 | Hutchison Medipharma Enterprises Limited | Cytokine inhibitors |
FR2939134A1 (fr) * | 2008-12-01 | 2010-06-04 | Sanofi Aventis | Derives de 6-cycloamino-3-(1h-pyrrolo°2,3-b!pyridin-4-yl) imidazo°1,2-b!-pyridazine, leur preparation et leur application en therapeutique |
FR2940285A1 (fr) | 2008-12-19 | 2010-06-25 | Sanofi Aventis | Derives de 6-cycloamino-2-thienyl-3-(pyridin-4-yl)imidazo °1,2-b!-pyridazine et 6-cycloamino-2-furanyl-3- (pyridin-4-yl)imidazo°1,2-b!-pyridazine, leur preparation et leur application en therapeutique |
FR2940284B1 (fr) * | 2008-12-19 | 2011-02-18 | Sanofi Aventis | Derives de 6-cycloamino-2,3-di-pyridinyl-imidazo°1,2-b!- pyridazine,leur preparation et leur application en therapeutique |
ES2497566T3 (es) | 2009-10-01 | 2014-09-23 | Cymabay Therapeutics, Inc. | Sales de tetrazol-1-il-fenoximetil-tiazol-2-il-piperidinil-pirimidina sustituida |
CN102781942B (zh) * | 2009-10-23 | 2015-09-23 | 詹森药业有限公司 | 用作食欲肽受体调节剂的二取代八氢吡咯并[3,4-c]吡咯 |
WO2011050202A1 (en) | 2009-10-23 | 2011-04-28 | Janssen Pharmaceutica Nv | Fused heterocyclic compounds as orexin receptor modulators |
EP2491034B1 (en) | 2009-10-23 | 2013-12-18 | Janssen Pharmaceutica, N.V. | Fused heterocyclic compounds as orexin receptor modulators |
CN102596961B (zh) | 2009-10-30 | 2015-12-02 | 詹森药业有限公司 | 咪唑并[1,2-b]哒嗪衍生物及其作为PDE10抑制剂的用途 |
AR080754A1 (es) | 2010-03-09 | 2012-05-09 | Janssen Pharmaceutica Nv | Derivados de imidazo (1,2-a) pirazina y su uso como inhibidores de pde10 |
WO2011163090A1 (en) | 2010-06-23 | 2011-12-29 | Metabolex, Inc. | Compositions of 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine |
RU2562833C2 (ru) | 2010-08-09 | 2015-09-10 | НБ Хелс Лаборатори Ко. Лтд. | Ингибитор казеинкиназы 1 дельта и казеинкиназы 1 е |
CN103298460B (zh) | 2010-12-14 | 2016-06-01 | 电泳有限公司 | 酪蛋白激酶1δ(CK1δ)抑制剂 |
WO2012145581A1 (en) | 2011-04-20 | 2012-10-26 | Janssen Pharmaceutica Nv | Disubstituted octahy-dropyrrolo [3,4-c] pyrroles as orexin receptor modulators |
BR112013033375B1 (pt) | 2011-06-27 | 2022-05-10 | Janssen Pharmaceutica N.V | Derivados de 1-aril-4-metil-[1,2,4]triazolo[4,3-a]quinoxa-lina, seu uso, composição farmacêutica que os compreende, processo de preparação dos mesmos, solução estéril e composto intermediário |
AU2013283426B2 (en) | 2012-06-26 | 2018-02-22 | Janssen Pharmaceutica Nv | Combinations comprising PDE 2 inhibitors such as 1-aryl-4-methyl- [1,2,4] triazolo [4,3-a] quinoxaline compounds and PDE 10 inhibitors for use in the treatment of neurological or metabolic disorders |
ES2607184T3 (es) | 2012-07-09 | 2017-03-29 | Janssen Pharmaceutica, N.V. | Inhibidores de la enzima fosfodiesterasa 10 |
WO2014100540A1 (en) * | 2012-12-21 | 2014-06-26 | Bristol-Myers Squibb Company | Pyrazole substituted imidazopyrazines as casein kinase 1 d/e inhibitors |
JP6267231B2 (ja) * | 2012-12-21 | 2018-01-24 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | カゼインキナーゼ1δ/ε阻害剤としての新規な置換イミダゾール |
GB201321734D0 (en) * | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic Agents |
WO2015106158A1 (en) * | 2014-01-09 | 2015-07-16 | Intra-Cellular Therapies, Inc. | Organic compounds |
CN108883110B (zh) | 2016-03-10 | 2022-05-27 | 詹森药业有限公司 | 使用食欲素-2受体拮抗剂治疗抑郁症的方法 |
JP2019527693A (ja) | 2016-08-03 | 2019-10-03 | サイマベイ・セラピューティクス・インコーポレイテッドCymaBay Therapeutics,Inc. | 炎症性胃腸疾患または胃腸状態を治療するためのオキシメチレンアリール化合物 |
EA201992215A1 (ru) | 2017-03-20 | 2020-02-06 | Форма Терапьютикс, Инк. | Пирролопирроловые композиции в качестве активаторов пируваткиназы (pkr) |
CN111989327A (zh) | 2018-02-05 | 2020-11-24 | 奥克梅斯公司 | 用于治疗疼痛的化合物 |
EP3852791A4 (en) | 2018-09-19 | 2022-06-15 | Forma Therapeutics, Inc. | ACTIVATION OF PYRUVATE KINASE R |
US20220031671A1 (en) | 2018-09-19 | 2022-02-03 | Forma Therapeutics, Inc. | Treating sickle cell disease with a pyruvate kinase r activating compound |
TW202112368A (zh) | 2019-06-13 | 2021-04-01 | 荷蘭商法西歐知識產權股份有限公司 | 用於治療有關dux4表現之疾病的抑制劑組合 |
US20230192699A1 (en) * | 2020-03-27 | 2023-06-22 | Gritscience Biopharmaceuticals Co., Ltd. | Compounds as casein kinase inhibitors |
CN115335057A (zh) * | 2020-03-27 | 2022-11-11 | 北京原基华毅生物科技有限公司 | 抑制酪蛋白激酶的方法 |
CA3235146A1 (en) | 2021-10-14 | 2023-04-20 | Incyte Corporation | Quinoline compounds as inhibitors of kras |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1989001333A1 (en) * | 1987-08-07 | 1989-02-23 | The Australian National University | IMIDAZO[1,2-b]PYRIDAZINES |
KR100722176B1 (ko) | 1999-06-08 | 2007-05-29 | 아벤티스 파마슈티칼스 인크. | 일주기 리듬 단백질을 변화시키기 위한 스크리닝 방법 |
PL1747220T3 (pl) * | 2003-12-11 | 2009-09-30 | Aventis Pharma Inc | Podstawione 1H-pirolo[3,2-b, 3,2-c i 2,3-c]pirydyno-2-karboksyamidy oraz pokrewne analogi jako inhibitory kinazy kazeinowej l epsilon |
CA2555263A1 (en) * | 2004-02-12 | 2005-09-01 | Neurogen Corporation | Imidazo-pyridazines, triazolo-pyridazines and related benzodiazepine receptor ligands |
GB0515026D0 (en) * | 2005-07-21 | 2005-08-31 | Novartis Ag | Organic compounds |
WO2007013673A1 (en) * | 2005-07-29 | 2007-02-01 | Astellas Pharma Inc. | Fused heterocycles as lck inhibitors |
DE102005042742A1 (de) * | 2005-09-02 | 2007-03-08 | Schering Ag | Substituierte Imidazo[1,2b]pyridazine als Kinase-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel |
-
2007
- 2007-07-19 FR FR0705224A patent/FR2918986B1/fr active Active
-
2008
- 2008-07-15 PA PA20088789901A patent/PA8789901A1/es unknown
- 2008-07-17 UY UY31236A patent/UY31236A1/es not_active Application Discontinuation
- 2008-07-17 TW TW097127189A patent/TW200914456A/zh unknown
- 2008-07-17 PE PE2008001220A patent/PE20090493A1/es not_active Application Discontinuation
- 2008-07-18 CN CN200880103986A patent/CN101784552A/zh active Pending
- 2008-07-18 BR BRPI0814510-5A2A patent/BRPI0814510A2/pt not_active IP Right Cessation
- 2008-07-18 CA CA2693116A patent/CA2693116A1/fr not_active Abandoned
- 2008-07-18 EA EA201070161A patent/EA016376B1/ru not_active IP Right Cessation
- 2008-07-18 JP JP2010516539A patent/JP5431319B2/ja not_active Expired - Fee Related
- 2008-07-18 WO PCT/FR2008/001057 patent/WO2009037394A2/fr active Application Filing
- 2008-07-18 AR ARP080103097A patent/AR069272A1/es unknown
- 2008-07-18 ES ES08831515T patent/ES2429765T3/es active Active
- 2008-07-18 EP EP08831515.5A patent/EP2178879B1/fr active Active
- 2008-07-18 NZ NZ582683A patent/NZ582683A/en not_active IP Right Cessation
- 2008-07-18 KR KR1020107001087A patent/KR20100041771A/ko not_active Application Discontinuation
- 2008-07-18 AU AU2008300449A patent/AU2008300449A1/en not_active Abandoned
- 2008-07-18 CL CL2008002138A patent/CL2008002138A1/es unknown
-
2010
- 2010-01-11 US US12/685,030 patent/US8455491B2/en not_active Expired - Fee Related
- 2010-01-19 CO CO10004823A patent/CO6290690A2/es not_active Application Discontinuation
- 2010-02-17 MA MA32629A patent/MA31616B1/fr unknown
- 2010-02-19 ZA ZA2010/01214A patent/ZA201001214B/en unknown
-
2013
- 2013-05-06 US US13/887,845 patent/US9108971B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
EA201070161A1 (ru) | 2010-08-30 |
CN101784552A (zh) | 2010-07-21 |
BRPI0814510A2 (pt) | 2015-02-03 |
WO2009037394A3 (fr) | 2009-06-18 |
CO6290690A2 (es) | 2011-06-20 |
EP2178879A2 (fr) | 2010-04-28 |
FR2918986A1 (fr) | 2009-01-23 |
KR20100041771A (ko) | 2010-04-22 |
CA2693116A1 (fr) | 2009-03-26 |
EA016376B1 (ru) | 2012-04-30 |
US20100152157A1 (en) | 2010-06-17 |
PA8789901A1 (es) | 2009-02-09 |
WO2009037394A2 (fr) | 2009-03-26 |
UY31236A1 (es) | 2009-03-02 |
MA31616B1 (fr) | 2010-08-02 |
NZ582683A (en) | 2011-07-29 |
AR069272A1 (es) | 2010-01-13 |
US8455491B2 (en) | 2013-06-04 |
US20130245023A1 (en) | 2013-09-19 |
FR2918986B1 (fr) | 2009-09-04 |
ZA201001214B (en) | 2011-05-25 |
CL2008002138A1 (es) | 2009-10-23 |
US9108971B2 (en) | 2015-08-18 |
AU2008300449A1 (en) | 2009-03-26 |
EP2178879B1 (fr) | 2013-07-03 |
JP5431319B2 (ja) | 2014-03-05 |
ES2429765T3 (es) | 2013-11-15 |
JP2010533686A (ja) | 2010-10-28 |
TW200914456A (en) | 2009-04-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20090493A1 (es) | DERIVADOS DE LA 6-CICLOAMINO-3-(PIRIDAZIN-4-IL)IMIDAZO[1,2-b]-PIRIDAZINA, SU PREPARACION Y SU APLICACION EN TERAPEUTICA | |
JP6385954B2 (ja) | キナーゼ調節のための化合物および方法、ならびにその適応 | |
JP2018519343A5 (es) | ||
PE20190336A1 (es) | Nuevos derivados de amonio, un proceso para su preparacion y composiciones farmaceuticas que los contienen | |
PE20150218A1 (es) | Nuevos derivados fosfatos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen | |
PE20090506A1 (es) | DERIVADOS DE IMIDAZO-[1,2-b]-PIRIDAZIN COMO INHIBIDORES DE ALK5 Y/O ALK4 | |
PE20110545A1 (es) | Compuestos de triazolopiridina como inhibidores de jak | |
PE20130012A1 (es) | Derivados de pirazol como inhibidores de jak | |
AR074052A1 (es) | Compuestos pirazolo{1,5-a}pirimidina sustituida como inhibidores de trk cinasa | |
PE20110572A1 (es) | DERIVADOS DE IMIDAZO[1,2-a]PIRIDINA COMO INHIBIDORES DE MET | |
AR053728A1 (es) | Pirimidinas condensadas como agonistas del receptor de acido nicotinico para el tratamiento de dislipidemia y composiciones farmaceuticas que las contienen en combinacion con otros agentes terapeuticos | |
PE20090714A1 (es) | Imidazopiridazinas y pirrolo-pirimidinas sustituidas como inhibidores de cinasa de lipido | |
PE20090370A1 (es) | Derivados de heterociclo fusionado como inhibidores de quinasa | |
EA023824B1 (ru) | ПРОИЗВОДНЫЕ 3,4-ДИГИДРОПИРРОЛО[1,2-a]ПИРАЗИН-1-ИЛАМИНА, ПРИГОДНЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ БЕТА-СЕКРЕТАЗЫ (BACE) | |
PE20140390A1 (es) | Derivados de imidazo[1,2-b]piridazina e imidazo[4,5-b]piridina como inhibidores de jak | |
PE20161246A1 (es) | Acrilamidas de pirrolo[2,3-d]pirimidinilo, pirrolo[2,3-b]pirazinilo y pirrolo[2,3-d]piridinilo | |
PE20151249A1 (es) | Derivados de pirazolopirimidina como inhibidores de jak quinasas | |
PE20130611A1 (es) | Triazolopiridinas sustituidas | |
AR093077A1 (es) | ANTAGONISTAS DE mGlu2/3 PARA EL TRATAMIENTO DE LOS TRASTORNOS AUTISTAS | |
PE20120534A1 (es) | PIRIMIDINAS FUSIONADAS COMO INHIBIDORES DE Akt | |
PE20141351A1 (es) | Triazolopiridinas | |
PE20090651A1 (es) | Derivados de isoquinolinilo e isoindolinilo como antagonistas de histamina-3 | |
PE20110560A1 (es) | NUEVOS DERIVADOS DE TRIAZOLO[4,3-a]PIRIDINA, SU PROCEDIMIENTO DE PREPARACION, SU APLICACION COMO MEDICAMENTOS, COMPOSICIONES FARMACEUTICAS Y NUEVA UTILIZACION PARTICULARMENTE COMO INHIBIDORES DE MET | |
PE20090960A1 (es) | Derivados de quinazolinadiona, su preparacion y sus aplicaciones terapeuticas | |
PE20090944A1 (es) | PIRIMIDINAS BICICLICAS FUSIONADAS COMO INHIBIDORES DE LA VIA Pi3K/AKT |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Refusal |